Immune Pharmaceuticals Inc. (IMNP)
Our attorneys are investigating customer losses in Immune Pharmaceuticals Inc., an investment offered and sold by National Securities Corporation Inc. (NSC) to its retail clients.
If you have suffered losses in Immune Pharmaceuticals Inc., please contact our lawyers for a free and confidential consultation concerning your legal rights and the possibility of recovery.
At Silver Law Group, we know from experience that not every investment recommended and solicited by a stockbroker is suitable and appropriate for the customer. We have seen, particularly in the initial public offering (IPO) space, that investors are often falsely promised high returns and low risk, when in truth the investment is speculative and subject to the loss of principal. Your financial advisor and the securities firm who sells the investment have a legal duty to fully explain the nature of the investment, its inherent risks and the possibility of loss.
Brokers and financial advisors may push risky initial public offerings on unsuspecting investors based upon strong financial incentives, including large commission payouts. Investors in such offerings must realize that these investments are inherently risky and should be considered very carefully before making a decision to invest. Representations made by stockbrokers that such investments are “safe” and “guaranteed” are typically false and are a red flag of possible fraud.National Securities Corporation Inc. Role in the Investment:
In 2014, National Securities Corporation underwrote Immune Pharmaceuticals Inc.’s stock offering. At the close of the offering, National Securities Corporation raised over 8 million ($8,625,000.00). Immune Pharmaceuticals Inc. was listed on the Nasdaq under the stock symbol “IMNP”. As of November 14, 2017, Immune Pharmaceuticals Inc. stock is worth $0.87 per share.Immune Pharmaceuticals Inc. Company Profile:
Immune Pharmaceuticals is a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases. Immune’s lead program, bertilimumab, is a first-in-class, fully human monoclonal antibody that targets and lowers levels of eotaxin-1, a chemokine that plays a role in immune responses and attracts eosinophils to the site of inflammation.
Silver Law Group represents investment fraud victims in cases to recover their investment losses. If you have questions about your legal rights, please contact Scott Silver of the Silver Law Group for a free consultation at firstname.lastname@example.org or toll-free at (800) 975-4345.